

IMpACT meeting at the Sanibel ADHD meeting, December 12, 2010

Present: Andreas, Bru, Toni, Eric, Alejandro Arias Vasquez, Phil, Steve, Jan H., Barbara (minutes)

Agenda

1. Update on papers/projects
2. IMpACT database and website
3. CINP in Stockholm June 3-7 2012: who is interested to speak there?
4. New types of projects/papers: interdisciplinary work?
5. Bergen meeting planning
6. EU project planning
7. A PhD student for IMpACT: can we provide start-up financing for the first years and how to organize such a project?

Ad 1) Update on papers/projects

- The US group has now finished genotyping SNPs in CDH13, which will be included in the meta-analysis performed by the German IMpACT group.
- The manuscript on DIRAS2 is under review at Neuropsychopharmacology.
- The DRD4 manuscript is under review at the American Journal of Medical Genetics Part B.
- The paper on the dopaminergic gene set is under review at the World Journal of Biological Psychiatry.
- The adult ADHD review is under review at Molecular Psychiatry.
- We plan to write an additional, more phenotype-centred review on adult ADHD, including text that had been put together for the white paper and the original first review. Nevertheless, with a number of additional reviews on adult ADHD having been published recently, we have to find our niche. We think that including aspects of adult ADHD frequency, phenotyping (with a recommendation of the tools to use for phenotyping) and diagnostic issues (DSM-IV to DSM-V, ICD10), data on health-care related costs, as well as naming key-areas in which additional research is recommended/required will give our review added value. A potentially suitable journal for the review is Psychopharmacology.
- When the database is finished, we should analyze the data to look at differences between the cultures and what is most consistent across cultures.
- Jan H. got funded for a large project to build an excellence centre for psychiatric disorders. This will include exome studies in adult ADHD, including up to 100 families within the next few years.

Ad 2) Database and website

- The database is half-filled, two of the other groups have indicated that they will send the data within the next few weeks.
- Nijmegen is going to set up a website that will serve three purposes:
 - Platform to show IMpACT to the world
 - Home for the database (protected area), and platform for exchange between IMpACT members
 - Testing platforms with online questionnaires and (cognitive) tests for patients and controls

Ad 3) CINP meeting in Stockholm (June 3-7, 2010)

Peter is planning on submitting a proposal for a symposium there and has asked for IMpACT PIs interested in presenting there. Phil, Toni, Andreas and Jan H. want to participate.

Ad 4) New types of projects/papers: interdisciplinary work

- We want to make more use of the additional expertise/possibilities we have within IMpACT by performing some studies including other aspects than gene – clinical phenotype associations. We could add neuroimaging, sequencing, cell modeling, protein studies, for example. The question is how to pick the right genes for such endeavors. While the GWAS still needs to be performed, we decide to choose a cross-disorder input and look at the SNPs coming from the PGC cross-disorder analyses (also include *CACNB2* from the ADHD-autism analysis). Eric will run those through the ADHD meta-analysis data to see if there is any signal in ADHD. Those that are positive, will then be tested in IMpACT in a MassArray analysis, either by Cigene(?) or by Andreas' group in Germany. We can then look for signals also in the (structural and functional) neuroimaging data of our different groups and see if rare variants can be found and if the genes can be investigated in cell/animal models and protein studies.
- If we plan additional IMpACT candidate gene studies, the responsibilities regarding responsibilities for writing up the work, as well as a time line for this, should be decided on beforehand.
- Phil is working with David Collier who has set up an CNV custom array for psychiatric disorders, in which his IMpACT samples are being taken along (free of charge). He will enquire if it is possible to include additional samples.

Ad 5)+6) Bergen IMpACT meeting and EU project

- The Bergen meeting will be scheduled to take 2 full days, with educational talks by the different sites open to all interested researchers and more dedicated meetings for the IMpACT PIs. This latter aspect had been rather short in Wuerzburg and planned at the end of the meeting, but should receive more time in Bergen.
- Given the need for an interdisciplinary project for the EU, we should think of non-IMpACT members that we would like to collaborate with in such a project and that bring expertise to the group that we do not currently have.
- Groups also request the possibility to present (data from) studies at their centres that are not part of IMpACT but might be interesting to our group.
- Buzzwords for our EU project are 'translational' and 'personalized'. Also, we cannot only focus on adults with ADHD, but should include a more lifespans approach. One idea on how this could be achieved is by choosing the family of an adult ADHD-affected individual as the unit, looking at aspects of parenting style and other family aspects to personalize the treatment of patients.

Ad 7) A PhD student for IMpACT

- Holland indicates to have start-up financing for 1 year for the student, Germany could find finances for an additional 6 months. For the rest, money is tight. Appointing the student in Spain would be cheapest, but would bring some problems with administration, if the student would be paid from different countries, although this might be solved by using a Foundation at Bru's university.
- We feel that the negative aspects of asking money from industry outweigh the positive sides.
- We will keep looking for funding opportunities for a collaborative PhD student.

To do list:

- **Eric/Steve**: Ask PGC for SNPs from cross-disorder analyses.
- **Eric**: Run PGC hits through childhood ADHD meta-analysis data and select those with interesting results.
- **Phil**: Check if additional IMpACT samples can be taken along in the CNV analyses of David Collier's.